RG7893
| RG7893 | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
RG7893 is an investigational drug developed for the treatment of autoimmune diseases. It is a monoclonal antibody designed to target specific pathways involved in the immune response. RG7893 is currently undergoing clinical trials to evaluate its efficacy and safety in patients with conditions such as rheumatoid arthritis and systemic lupus erythematosus.
Mechanism of Action[edit]
RG7893 functions by selectively inhibiting a key cytokine involved in the inflammatory process. This cytokine, known as interleukin-6 (IL-6), plays a crucial role in the pathogenesis of various autoimmune disorders. By blocking IL-6, RG7893 aims to reduce inflammation and modulate the immune system's activity, thereby alleviating symptoms associated with these diseases.
Clinical Trials[edit]
RG7893 is currently in Phase II clinical trials. Preliminary results have shown promise, with patients experiencing a reduction in disease activity and improved quality of life. The trials are designed to assess the optimal dosing regimen, long-term safety, and potential side effects of the drug.
Potential Side Effects[edit]
As with any investigational drug, RG7893 may have side effects. Commonly reported adverse effects include injection site reactions, headache, and nausea. More serious side effects, although rare, may include infections due to immunosuppression and liver function abnormalities.
Future Directions[edit]
The development of RG7893 represents a significant advancement in the treatment of autoimmune diseases. Ongoing research aims to further elucidate its mechanism of action and expand its therapeutic applications. Future studies may explore its use in other inflammatory conditions such as Crohn's disease and psoriasis.
Also see[edit]
- Monoclonal antibody therapy
- Autoimmune disease
- Interleukin-6
- Rheumatoid arthritis
- Systemic lupus erythematosus
| Hypersensitivity and autoimmune diseases (279.5–6) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa
Tired of being overweight?
Special offer:
Budget GLP-1 weight loss medications
- Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
- Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay
✔ Same-week appointments, evenings & weekends
Learn more:
- GLP-1 weight loss clinic NYC
- W8MD's NYC medical weight loss
- W8MD Philadelphia GLP-1 shots
- Philadelphia GLP-1 injections
- Affordable GLP-1 shots NYC
|
WikiMD Medical Encyclopedia |
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
